With payors and providers increasingly focused on the cost effectiveness of healthcare, the demand for more detailed outcomes information is growing. National and European regulatory authorities and corporate institutions such as the UK’s the National Institute for Health and Clinical Excellence (NICE) in England and Wales are increasingly reliant on this data to fully understand a product's value in healthcare and its potential impact in real world clinical practice. Achieving a favourable endorsement from these bodies is critical to ensuring that new innovations reach the market and patients more quickly and are incorporated into appropriate guidelines of care.
In seeking to supply this information, companies are increasingly faced with the need for data, analyses and modelling expertise to support a product's benefits and anticipated consequences. Following the recent expansion of its consulting and service offerings in health economics and outcomes research, which now include the combined expertise of Belgium's Health Economics and Disease Management (HEDM), the GYD institut in France, Fricke & Pirk in Germany, MTAG in the UK and Australia, HOR Europe in Spain, CORE in Switzerland and PharMetrics in the USA, IMS is uniquely positioned to help our clients demonstrate clinical outcomes and win economic arguments based on unmatched evidence-based pharmaceutical and medical data drawn from real world observation.
IMS now offers consulting expertise in the following areas to support the use of outcomes measures in health care resource allocation decisions:
- Health economic model development and evaluation
- Cost-of-illness studies and disease management models
- Health and budget impact analyses
- Willingness to pay surveys
- Global and local understanding of health care practices and policies
- Design and analysis of prospective studies
The unique value of longitudinal data
At the heart of IMS’s research capabilities in this area is IMS Disease Analyzer, a unique longitudinal patient database that tracks patients and their resource use across a variety of treatment pathways in four European countries. This rich data source, combined with IMS medical and hospital data and information on product pricing in the majority of countries worldwide, provides a full and realistic picture of:
- Hospital and referral rates
- Cost of medicines (first-line, second-line, to treat adverse events)
- Other interventions
- Outcomes of treatment (reduction in blood pressure, etc)
- Co-morbidities
- Treatment persistence and compliance
The integration of IMS’s longitudinal disease information from GPs and medical hospital data with HEDM’s and GYD’s modelling expertise enables our clients to:
- achieve effective penetration of pharmaceutical products into health care systems in the major markets
- develop information support for health care systems to utilise products effectively
- understand and meet the needs of clinicians, other providers and health care managers and third party payers/reimbursement authorities
- utilise economic and outcomes information and the use of disease models as part of an overall pricing and health care strategy
- develop cost benefit and budgetary impact analyses based on sophisticated modelling techniques
In addition we have data expertise via Pharmetrics, IMS Oncology Analyzer and Acute cardiovascular databases.
View more at our IMS HEOR microsite here.